Saturday 17 October 2026
Export MBX’s income statement to Excel — free account
MBX Biosciences, Inc.
In the quarter to June 2026, EPS fell 34.5% and free cash flow fell 29.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
49.61
1.10
−2.17%
Follow MBX
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 15.31 | 4.81 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 27.50 | 35.55 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 36 | 43 | 63 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | — | — | (26) | (33) | (62) | (87) | |||||
| EBT margin, % | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | — | — | (26) | (33) | (62) | (87) | |||||
| Depreciation | — | — | — | — | — | — | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | (39.18) | (31.96) | (5.82) | (2.38) | |||||
| Cash flow | — | — | — | — | — | — | (34.67) | (31.38) | (5.14) | (2.19) | |||||
| Capex | — | — | — | — | — | — | (0.66) | (0.13) | (0.08) | (0.05) | |||||
| Free cash flow | — | — | — | — | — | — | (35.33) | (31.51) | (5.22) | (2.24) | |||||
| Book value | — | — | — | — | — | — | (63.88) | (71.12) | 24.19 | 10.11 | |||||
| Shares, m | — | — | — | — | — | — | 1 | 1 | 11 | 37 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (23) | (32) | (55) | (80) | ||||
| Capex | — | — | — | — | — | — | 0 | 0 | (1) | (2) | |||||
| Free cash flow | — | — | — | — | — | — | (24) | (32) | (56) | (82) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | 41 | 80 | 256 | 366 | ||||
| Total debt | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | — | — | (42) | (81) | (262) | (374) | |||||
| Shareholders’ equity | — | — | — | — | — | — | (43) | (72) | 257 | 369 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (50.38) | (35.11) | (26.61) | ||||
| ROIC | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | — | 0.00 | 56.60 | (66.95) | (27.76) | |||||
Negative figures in brackets.
Charts ten years each
MBX Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ZLAB Zai Lab Limited Unsponsored ADR | $2.7B | — (loss-making) | — (loss-making) | −3.33% (below 0%: shrinking) | n/m | −84.42% (below 0%: shrinking) | 54.70% | (71.95%) | Compare |
| PGEN Precigen, Inc. | $2.6B | — (loss-making) | — (loss-making) | +6,322.66% (above 0%: growing) | n/m | +8.73% (above 0%: growing) | 94.90% | 41.18% | Compare |
| BEAM Beam Therapeutics Inc. | $2.6B | — (loss-making) | — (loss-making) | −94.21% (below 0%: shrinking) | n/m | +13.92% (above 0%: growing) | 100.00% | (25,827.14%) | Compare |
| NAMS NewAmsterdam Pharma Company N.V. | $2.5B | — (loss-making) | — (loss-making) | −80.67% (below 0%: shrinking) | n/m | −4.07% (below 0%: shrinking) | 100.00% | (1,752.61%) | Compare |
| MBX MBX Biosciences, Inc. | $2.4B | — (loss-making) | — | — | n/m | −29.67% (below 0%: shrinking) | — | 0.00% | |
| ADMA ADMA Biologics Inc | $2.4B | 14.8× | 9.5× | +1.98% (above 0%: growing) | +21.43% (above 0%: growing) | +19.72% (above 0%: growing) | 69.36% | 42.16% | Compare |
| SLS SELLAS Life Sciences Group, Inc. | $2.3B | — (loss-making) | — (loss-making) | −57.10% (below 0%: shrinking) | n/m | −3.52% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CLDX Celldex Therapeutics, Inc. | $2.3B | — (loss-making) | — (loss-making) | −96.83% (below 0%: shrinking) | n/m | −35.45% (below 0%: shrinking) | 100.00% | (366,468.18%) | Compare |
| AUPH Aurinia Pharmaceuticals Inc | $2.2B | 6.9× | 16.5× | +18.87% (above 0%: growing) | +81.25% (above 0%: growing) | +19.08% (above 0%: growing) | 92.12% | 48.19% | Compare |
| Median of peers | $2.4B | — | — | −30.21% | — | +2.61% | 93.51% | (35.97%) |
MBX Biosciences, Inc. (MBX) key facts
- MBX Biosciences, Inc. (MBX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, MBX traded at $49.61, a market capitalization of $2.4 billion.
- Return on equity was −27.8% and debt-to-equity 0.00.